Misoprostol for Secondary Prevention of Postpartum Hemorrhage at the Community Level in India

NCT01462422 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 3032

Last updated 2014-06-16

No results posted yet for this study

Summary

This study compares two community-level strategies: selective administration of 800 mcg sublingual misoprostol to women at 350 mL blood loss for secondary prevention of postpartum hemorrhage (PPH) with universal use of 600 mcg oral misoprostol at the time of delivery for primary prevention of PPH. The study hypothesizes that at community-level births, secondary prevention for women is non-inferior (based on clinical parameters) to universal prophylaxis provided to women for primary prevention of PPH. This cluster-design non-inferiority trial has the potential to inform service delivery programs on clinical outcomes, program feasibility, cost and acceptability of two different community models of PPH care using misoprostol.

Conditions

  • Postpartum Hemorrhage

Interventions

DRUG

Misoprostol

Selective administration of 800 mcg sublingual misoprostol to women with at least 350 mL blood loss within 1 hour following delivery

DRUG

Misoprostol

Universal administration of 600 mcg oral misoprostol given to all women within 5 minutes of delivery of the baby

Sponsors & Collaborators

  • Sri B. M. Patil Medical College, Bijapur, Karnataka, India

    collaborator UNKNOWN
  • Jawaharlal Nehru Medical College

    collaborator OTHER
  • University of Illinois at Chicago

    collaborator OTHER
  • University of California, San Francisco

    collaborator OTHER
  • Gynuity Health Projects

    lead OTHER

Principal Investigators

  • Beverly Winikoff, MD, MPH · Gynuity Health Projects

  • Sheila Raghavan, MSc · Gynuity Health Projects

  • Stacie Gellar, PhD · University of Illinois at Chicago

  • Suellen Miller, PhD, CNM · University of California, San Francisco

  • Shivaprasad S Goudar, MD, MHPE · Jawaharlal Nehru Medical College

Study Design

Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
15 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-12-31
Primary Completion
2014-03-31
Completion
2014-03-31

Countries

  • India

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01462422 on ClinicalTrials.gov